The University of Michigan Hybridoma Core provides research services in custom monoclonal antibody development (mAb) and bulk production of monoclonal antibodies from established hybridomas (somatic cell hybrids). The Core has developed monoclonal antibodies against a wide variety of lymphocyte surface antigens, tumor cell antigens, purified proteins, hormones, hormone receptors and recombinant proteins and peptides. Services are available to all University of Michigan investigators as well as to other institutions and the private sector.

This Hybridoma Core facility has been in continuous operation since its establishment in 1980 under the leadership of the Michigan Diabetes Research and Training Center. The Core is currently supported by recharges for the cost of services and is managed by the Internal Medicine Division of Rheumatology. We are committed to providing high quality, cost effective services, from a well-trained staff to our researchers.